ArticleThe Journal of antibiotics2026
Pobacilamides A and B, two linear depsipeptides from a marine-derived Bacillus sp. ROA-056.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Through the intensive investigation of the chemical components for the culture broth of marine-derived Bacillus sp. ROA-056, two new linear peptides, namely, pobacilamides A (1) and B (2), have been discovered. Their planar structures were elucidated through mass spectrometry, and 1D and 2D NMR analyses. Both peptides were composed of valine (Val), 2-hydroxyisovaleric acid (HIVA), and 2-hydroxyisocaproic acid (HICA), while pobacilamide A (1) contained leucine (Leu). The absolute configurations of Val and Leu were defined by acid hydrolysis and advanced Marfey's method, while those of HIVA and HICA were established by GC-MS analysis of O-trifluoroacetylated (S)-(+)-3-methyl-2-butyl ester. Compounds 1 and 2 displayed selective antibacterial activity against Gram-positive bacteria, including Bacillus subtilis and Kocuria rhizophila, with minimum inhibitory concentrations (MICs) values from 0.25 μg/mL to 4 μg/mL. Pobacilamide B (2) showed the strongest activity against K. rhizophila with an MIC of 0.25 μg/mL. No antibacterial activity was observed against Gram-negative strains. These results suggested that compounds 1 and 2 have considerable potential as targeted antibacterial agents for Gram-positive pathogens.
Identifiers
42919854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.